Skip to content

Geron GERN Free cash flow margin

Free cash flow margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
24.6%-2.9pp
Incyte logo
IncyteINCY
28.2%+19.7pp
Immunome logo
ImmunomeIMNM
-5,118.9%-8,601pp
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-187.2%-85.4pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-207.2%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-250.1%-49.4pp

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
Enterprise value$973.78M-5.3%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Calculated from Geron’s reported figures.

Based on trailing twelve months.

The official record: Geron’s 10-Q, filed November 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Geron's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's free cash flow margin?
Geron (GERN) reported free cash flow margin of -734.4% in Q3 2024.
How has Geron's free cash flow margin changed year-over-year?
Geron's free cash flow margin increased by 98.6% year-over-year, from -51,385.5% to -734.4%.
What is the long-term trend for Geron's free cash flow margin?
Over 3 years (2020 to 2023), Geron's free cash flow margin has grown at a 39.0% compound annual growth rate (CAGR), from -26,503.2% to -71,127.8%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.